通过靶向 TROP2 的 CAR-T 细胞疗法清除 EGFR 突变非小细胞肺癌中的耐药持留细胞
Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
73.0分
★★★★☆
站内排序·非疗效
DISEASE HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
Synergistic Antitumor Efficacy of Radiofrequency Ablation Combined With TROP2-CAR-T Cells in a Xenograft Mouse Model of Lung Adenocarcinoma.
RFA 与 TROP2-CAR-T 疗法联合在 LUAD 中显示出增强的抗肿瘤疗效和改善的安全性特征,凸显了一种有前景的联合免疫治疗策略。
Advances in adoptive cell therapies in small cell lung cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。